Actively Recruiting
Kinetics of INF-b3 Production in Intensive Care Patients Monitoring of INF-b3 in Intensive Care
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-05-19
200
Participants Needed
7
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the immune response in patients admitted to intensive care after severe trauma, high-risk surgery, or acute respiratory distress syndrome. These patients often experience an initial strong inflammation followed by an immune suppression phase, which increases the risk of infections and complications. The study aims to monitor interferon gamma (IFN-b3) production as a marker of immune function to better understand immune status changes in these critically ill patients. The study involves collecting blood samples daily from day 1 to day 7, then every 72 hours until the patient is discharged from intensive care or up to day 28. Blood will be taken using an arterial catheter already in place, and no extra procedures are required beyond routine care. This observational study will analyze IFN-b3 production and other immune markers such as mHLA-DR expression to characterize immune function over time. Participants will be monitored closely during their intensive care stay with regular blood tests to measure immune responses. Researchers will also collect data on infections, viral reactivations, mechanical ventilation duration, septic shock, renal impairment, and length of ICU stay. The main outcome measured is IFN-b3 production daily and then every 72 hours, with monitoring continuing up to 28 days or until ICU discharge.
CONDITIONS
Brief Title
Kinetics of INF-γ Production in Intensive Care Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Patients admitted to intensive care after severe trauma, or presenting with acute respiratory distress
- Patients undergoing cardiac, vascular, or digestive surgery with planned postoperative intensive care
You will not qualify if you...
- Expressed opposition from the patient, a relative, or legal representative
- Pregnant women
- Hemoglobin less than 7g/dl at inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 28 days or until discharge from intensive care
Participants are monitored in the intensive care unit with regular blood sampling to assess immune function and other health parameters.
Daily blood sampling from Day 1 to Day 7, then every 72 hours until discharge or Day 28
Trial Site Locations
Total: 7 locations
1
Reanimation department, Annecy Genevois hospital
Annecy, France, 74370
Not Yet Recruiting
2
Reanimation department, Clermont-Ferrand Hospital
Clermont-Ferrand, France, 63000
Not Yet Recruiting
3
Reanimation department, Lyon hospital
Lyon, France, 69003
Not Yet Recruiting
4
Réanimation cardio-chirurgicale - Pitié-Salpêtrière hospital
Paris, Île-de-France Region, France, 75013
Actively Recruiting
5
Réanimation chirurgicale Gaston Cordier - Pitié-Salpêtrière hospital
Paris, Île-de-France Region, France, 75013
Actively Recruiting
6
Réanimation chirurgicale Husson Mourrier - Pitié-Salpêtrière hospital
Paris, Île-de-France Region, France, 75013
Not Yet Recruiting
7
Réanimation neuro-chirurgicale - Pitié-Salpêtrière hospital
Paris, Île-de-France Region, France, 75013
Not Yet Recruiting
Research Team
J
Jean-michel Constantin, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here